Biotts

Biotts, a pioneering Polish-American biotech company, is focused on developing proprietary drugs in oncology, diabetology, and pain by leveraging unique formulations and drug delivery technologies. The company has made significant strides in the field with the breakthrough technology of its universal transdermal therapeutic system MTC-Y (Multifunctional Transdermal Carrier-Y). This carrier has demonstrated the ability to significantly enhance the bioavailability of active substances, allowing them to penetrate through the skin into soft tissues and bones. Notably, the carrier can be tailored for targeted action in pathologically changed tissues, enabling a reduction in therapeutic drug doses while maintaining efficacy and concurrently minimizing side effects. Furthermore, the system facilitates the transport of one to several active substances, providing opportunities to design multi-component drugs. Biotts, established in 2018, operates within the biotechnology sector and is headquartered in Poland. The company recently secured a Non-Equity Assistance investment on 05 October 2021, with Google for Startups participating as the investor. This strategic investment is expected to fuel the further development and advancement of Biotts' groundbreaking drug delivery technologies and proprietary drugs. With its innovative approach and strong investor support, Biotts is well-positioned to make significant contributions to the biotech industry, potentially revolutionizing the treatment landscape for oncology, diabetology, and pain management.